Statement: In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. 
Primary_evidence: Outcome Measurement:    Central Nervous System (CNS) Progression-free Survival(PFS)   The number of patients that are documented to have progression free survival at 3 months after treatment. Progression free is define as <25% increase in tumor area.   PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death.   Time frame: 3 months after treatment Results 1:    Arm/Group Title: Epothilone B: Group A   Arm/Group Description: Group A: Patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT). Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.   Overall Number of Participants Analyzed: 45   Measure Type: Number   Unit of Measure: participants  12 Results 2:    Arm/Group Title: Epothilone B: Group B   Arm/Group Description: Group B: an exploratory cohort of patients, with either leptomeningeal metastases (LMD) or unirradiated, asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.   Overall Number of Participants Analyzed: 10   Measure Type: Number   Unit of Measure: participants  2